PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
September 12, 2025Journal of Cystic FibrosisOpen Access

Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMordechai PollakSGSimone GambazzaAOAnnalisa Orenti

Discussion

Loading...

Member takes

Overview

Analysis identifies factors linked to sustained chronic pseudomonas aeruginosa infection in cystic fibrosis patients, suggesting possible intervention points.

Key Points

  • Among 8188 cystic fibrosis patients with chronic pseudomonas aeruginosa before treatment, 4908 remained infected after one year.
  • Older age and lower baseline ppFEV1 were identified as significant predictors of chronic infection status post-treatment.
  • Clinical outcomes improved similarly with elexacaftor treatment, regardless of whether patients shifted to non-chronic pseudomonas status.
  • Further research is needed to understand pseudomonas aeruginosa's role in cystic fibrosis lung disease in light of elexacaftor treatment.

Cite This Study

Pollak et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3831b076d99fa54d46https://doi.org/10.1016/j.jcf.2025.08.019
View Full Paper
Ask AI
Bookmark
Share